Product logins

Find logins to all Clarivate products below.


Regina Galera

Director, Regulatory and Clinical Consulting, Life Sciences and Healthcare

Regina is a MSc Industrial Pharmacist by the University of Barcelona with over 19 years of experience in the Pharmaceutical and Medical Device Industry. She is a seasoned professional within the Regulatory, Clinical, Quality and Vigilance fields across EMEA, North America, Latin America, Asia Pacific and Japanese markets.

She has experience both in Industry with international companies such as Alcon (Novartis), Smith & Nephew and Olympus as well as in Consulting (IQVIA) interacting with Competent Authorities, Notified Bodies, Certification Bodies and Third-party auditors. Among others, she has worked with ophthalmic drugs, antibiotics, anesthetics, aesthetic products, combination products, class I-III medical devices, including implantable, custom-made, active and software as a medical device (SaMD).

She leads a team of experienced consultants who are focused on developing strategic technology enabled customized Regulatory and Clinical solutions with a holistic approach for Pharmaceuticals, Biologics, Medical Devices, Combination products and Consumer Health covering more than 140 countries.


arrow_forward
Get in touch with Regina

Latest news

News November 6, 2025
Fujifilm Selects IPfolio from Clarivate

Maximizing the value of intellectual property assets to support business growth London, U.K. November 6, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that…

News October 30, 2025
Clarivate Pulse of the Library Report Reveals Link Between AI Literacy, AI Implementation and Confidence

Drawing on insights from over 2,000 librarians representing academic, national and public libraries globally, the report offers an up-to-date view of how they are adapting to rapid change London, U.K.,…

News October 29, 2025
Clarivate Reports Third Quarter 2025 Results

— Continued acceleration of organic ACV — — Raises 2025 Revenues Outlook — — Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter—  …

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025